Skip to main content

Consolidation Could Come Calling for Biotech in 2022

Expectations are in place for a brisk pace of consolidation in the biotechnology space this year, and that could benefit an assortment of exchange traded funds, such as the ALPS Medical Breakthroughs ETF (SBIO). Like other ETFs addressing smaller biotech stocks, SBIO is coming off a trying 2021,...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.